HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

NASDAQ:HSCS • US42254E3027

2.87 USD
+0.08 (+2.87%)
At close: Feb 26, 2026
3.1 USD
+0.23 (+8.01%)
After Hours: 2/12/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, HSCS scores 2 out of 10 in our fundamental rating. HSCS was compared to 185 industry peers in the Health Care Equipment & Supplies industry. HSCS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSCS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year HSCS has reported negative net income.
  • In the past year HSCS has reported a negative cash flow from operations.
  • In the past 5 years HSCS always reported negative net income.
  • In the past 5 years HSCS always reported negative operating cash flow.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

  • HSCS's Return On Assets of -150.70% is on the low side compared to the rest of the industry. HSCS is outperformed by 86.49% of its industry peers.
  • Looking at the Return On Equity, with a value of -216.05%, HSCS is doing worse than 73.51% of the companies in the same industry.
Industry RankSector Rank
ROA -150.7%
ROE -216.05%
ROIC N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

  • HSCS has a Gross Margin (57.47%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of HSCS has grown nicely.
  • HSCS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, HSCS has more shares outstanding
  • HSCS has less shares outstanding than it did 5 years ago.
  • HSCS has a worse debt/assets ratio than last year.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • Based on the Altman-Z score of -19.96, we must say that HSCS is in the distress zone and has some risk of bankruptcy.
  • HSCS has a worse Altman-Z score (-19.96) than 88.65% of its industry peers.
  • There is no outstanding debt for HSCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.96
ROIC/WACCN/A
WACC9.7%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 2.42 indicates that HSCS has no problem at all paying its short term obligations.
  • HSCS has a Current ratio of 2.42. This is comparable to the rest of the industry: HSCS outperforms 48.11% of its industry peers.
  • HSCS has a Quick Ratio of 2.00. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.00, HSCS perfoms like the industry average, outperforming 54.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 74.25% over the past year.
  • Looking at the last year, HSCS shows a very negative growth in Revenue. The Revenue has decreased by -76.34% in the last year.
  • HSCS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -41.50% yearly.
EPS 1Y (TTM)74.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.56%
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, HSCS will show a very strong growth in Earnings Per Share. The EPS will grow by 28.44% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.35%
EPS Next 2Y28.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 500K 1M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
  • Also next year HSCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • HSCS's earnings are expected to grow with 28.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.44%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HSCS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HEARTSCIENCES INC

NASDAQ:HSCS (2/26/2026, 4:30:02 PM)

After market: 3.1 +0.23 (+8.01%)

2.87

+0.08 (+2.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-15
Earnings (Next)03-12
Inst Owners5.51%
Inst Owner Change12.69%
Ins Owners3.68%
Ins Owner Change75.21%
Market Cap9.13M
Revenue(TTM)8.70K
Net Income(TTM)-9.04M
Analysts82.5
Price Target10.81 (276.66%)
Short Float %1.38%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.14%
Min EPS beat(2)18.47%
Max EPS beat(2)57.81%
EPS beat(4)3
Avg EPS beat(4)22.01%
Min EPS beat(4)-6.31%
Max EPS beat(4)57.81%
EPS beat(8)5
Avg EPS beat(8)-35.56%
EPS beat(12)7
Avg EPS beat(12)-27.5%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.48%
EPS NQ rev (1m)7.61%
EPS NQ rev (3m)59.13%
EPS NY rev (1m)-0.81%
EPS NY rev (3m)41.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1049.03
P/FCF N/A
P/OCF N/A
P/B 2.18
P/tB 3.88
EV/EBITDA N/A
EPS(TTM)-6.88
EYN/A
EPS(NY)-3.28
Fwd EYN/A
FCF(TTM)-2.37
FCFYN/A
OCF(TTM)-2.36
OCFYN/A
SpS0
BVpS1.32
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -150.7%
ROE -216.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.47%
FCFM N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 145.29%
Cap/Sales 460.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2
Altman-Z -19.96
F-Score3
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)199.15%
Cap/Depr(5y)121.34%
Cap/Sales(3y)570.65%
Cap/Sales(5y)345.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.56%
EPS Next Y59.35%
EPS Next 2Y28.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.17%
OCF growth 3YN/A
OCF growth 5YN/A

HEARTSCIENCES INC / HSCS FAQ

What is the fundamental rating for HSCS stock?

ChartMill assigns a fundamental rating of 2 / 10 to HSCS.


Can you provide the valuation status for HEARTSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to HEARTSCIENCES INC (HSCS). This can be considered as Overvalued.


What is the profitability of HSCS stock?

HEARTSCIENCES INC (HSCS) has a profitability rating of 1 / 10.